Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy

Biochemical and Biophysical Research Communications

Volumn 410, Issue 2, 2011, Pages 218-223

  Fu, Yuejun ^a   Huang, Rui ^a   Zheng, Yali ^a   Zhang, Zhiyun ^a   Liang, Aihua ^a  

^a SHANXI UNIVERSITY   (China)

Author keywords

Chemotherapy; Gliomas; Isocitrate dehydrogenase 2 (IDH2); Tumorigenesis

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; ANTINEOPLASTIC AGENT; CYTARABINE; DACTINOMYCIN; DOXORUBICIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; NIMUSTINE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TENIPOSIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENE MUTATION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GLIOMA; ISOCITRATE DEHYDROGENASE; MUTATION; RATS;

RATTUS;

EID: 79959696548     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.108     Document Type: Article

References (25)

1. Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 2007, 170:1445-1453.
2. Ramachandran N., Colman R.F. Chemical characterization of distinct subunits of pig heart DPN-specific isocitrate dehydrogenase. J. Biol. Chem. 1980, 255:8859-8864.
3. Winkler B.S., DeSantis N., Solomon F. Multiple NADPH-producing pathways control glutathione (GSH) content in retina. Exp. Eye Res. 1986, 43:829-847.
4. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008, 116:597-602.
5. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
6. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 2009, 174:1149-1153.
7. Ichimura K., Pearson D.M., Kocialkowski S., Bäcklund L.M., Chan R., Jones D.T., Collins V.P. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro. Oncol. 2009, 11:341-347.
8. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., Weller M., Herold-Mende C., Unterberg A., Jeuken J.W., Wesseling P., Reifenberger G., von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol. 2009, 118:469-474.
9. Bleeker F.E., Lamba S., Leenstra S., Troost D., Hulsebos T., Vandertop W.P., Frattini M., Molinari F., Knowles M., Cerrato A., Rodolfo M., Scarpa A., Felicioni L., Buttitta F., Malatesta S., Marchetti A., Bardelli A. IDH1 mutations at residue p.R132 (IDH1 (R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 2009, 30:7-11.
10. Kang M.R., Kim M.S., Oh J.E., Kim Y.R., Song S.Y., Seo S.I., Lee J.Y., Yoo N.J., Lee S.H. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer 2009, 125:353-355.
11. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., Fulton L.A., Locke D.P., Magrini V.J., Abbott R.M., Vickery T.L., Reed J.S., Robinson J.S., Wylie T., Smith S.M., Carmichael L., Eldred J.M., Harris C.C., Walker J., Peck J.B., Du F., Dukes A.F., Sanderson G.E., Brummett A.M., Clark E., McMichael J.F., Meyer R.J., Schindler J.K., Pohl C.S., Wallis J.W., Shi X., Lin L., Schmidt H., Tang Y., Haipek C., Wiechert M.E., Ivy J.V., Kalicki J., Elliott G., Ries R.E., Payton J.E., Westervelt P., Tomasson M.H., Watson M.A., Baty J., Heath S., Shannon W.D., Nagarajan R., Link D.C., Walter M.J., Graubert T.A., DiPersio J.F., Wilson R.K., Ley T.J. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009, 36:1058-1066.
12. Park S.W., Chung N.G., Han J.Y., Eom H.S., Lee J.Y., Yoo N.J., Lee S.H. Absence of IDH2 codon 172 mutation in common human cancers. Int. J. Cancer 2009, 125:2485-2486.
13. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
14. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., Ding J., Lei Q., Guan K.L., Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265.
15. Pollard P.J., Ratcliffe P.J. Puzzling patterns of predisposition. Science 2009, 324:192-194.
16. Thompson C.B. Metabolic enzymes as oncogenes or tumor suppressors. N. Engl. J. Med. 2009, 360:813-815.
17. Hughes J.M., Groot A.J., van der Groep P., Sersansie R., Vooijs M., van Diest P.J., Van Noorden C.J., Schlingemann R.O., Klaassen I. Active HIF-1 in the normal human retina. J. Histochem. Cytochem. 2009, 58:247-254.
18. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-747.
19. Aghili M., Zahedi F., Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J. Neurooncol. 2009, 91:233-236.
20. Batinic-Haberle I., Benov L.T. An SOD mimic protects NADP+dependent isocitrate dehydrogenase against oxidative inactivation. Free Radic. Res. 2008, 42:618-624.
21. Grobben B., De Deyn P.P., Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 2002, 310:257-270.
22. Sampson J.H., Archer G.E., Bigner D.D. Use of experimental models in neuron-oncological research. Neurosurgery: the scientific basis of clinical practice 1999, 596. Blackwell Science, Oxford. 1st ed. A. Clockard, R. Hayward, J.T. Hoff (Eds.).
23. Holdhoff M., Parsons D.W., Diaz Jr L.A. Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. J. Neurooncol. 2009, 94:297.
24. Fu Y.J., Huang R., Du J., Yang R., An N., Liang A. Glioma-derived mutations in IDH: from mechanism to potential therapy. Biochem. Biophys. Res. Commun. 2010, 397:127-130.
25. J. Zhu, J.L. Zuo, Q. Xu, X. Wang, Z. Wang, D. Zhou, Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients, Med. Hypotheses. (2011) Online.